METAL CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY

肿瘤相关单抗是潜在的治疗药物 细胞毒剂对恶性细胞的选择性载体。我们正在测试 这一假说出现在几个动物模型系统中：一个是肿瘤病毒 诱导小鼠白血病，另一种是裸鼠裸鼠移植瘤 老鼠。 所使用的各种细胞杀伤剂是放射性同位素。他们的 与抗体结合时的相对治疗效果正在 进行检测，并与单抗比较。这些同位素 未被使用的包括具有高度杀瘤活性的阿尔法发射母体 放射性同位素铅-212或铋-212，以及贝塔粒子发射体， 运-90。不同络合物的合成及放射化学分离 这些目标所需的技术正在被设计并简化为临床应用 练习一下。同位素治疗的结果正在与那些 通过使用抗体结合的毒素或药物获得的 肿瘤生长、消退或治愈。 这些研究将为人类医学提供设计或 选择靶向细胞杀伤剂合理治疗恶性肿瘤 无论是肿瘤还是转移。

Tumor-associated monoclonal antibodies are potential therapeutic agents as selective carriers of cytotoxic agents to malignant cells. We are testing this hypothesis in several animal model systems: one is a tumor virus induced leukemia of mice, another is human tumor xenographs in nude athymic mice. The various cytocidal agents being employed are radioisotopes. Their relative therapeutic efficacy when conjugated to antibodies is being assayed and compared to that of monoclonal antibodies alone. The isotopes not being used include the highly tumoricidal alpha emitting parent radioisotopes Pb-212 or Bi-212, as well as the beta particle emitter, Y-90. The syntheses of differnet chelates and radiochemical separations required for these objectives are being devised and reduced to clinical practice. Results from isotopic therapy are being compared with those obtained by use of antibody conjugated toxins or drugs with respect to tumor growth, regression or cure. These studies will provide for human medicine a basis for design or rational therapy of malignancies by selectively targeting cytocidal agents to tumors as well as metastases.